SueWallSt

#127 $NKTR Trial Trouble When Clinical Confidence Cracks

Dive into the Nektar Therapeutics $NKTR controversy as we break down a securities class action tied to biotech trials, protocol violations, and alleged misleading statements around clinical execution. This episode is for investors, traders, and anyone following biotech stocks, drug development, and market risk. Expect deep dives, real case analysis, and insights into trial integrity, statistical outcomes, and stock reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#126 $MNDY Growth Story or Slowing Momentum Inside monday.com Shift

Dive into the monday.com $MNDY controversy as we break down a securities class action tied to SaaS growth, enterprise sales trends, and shifting long term revenue targets. This episode is for investors, traders, and anyone following tech stocks, cloud platforms, and market volatility. Expect deep dives, real case analysis, and insights into slowing customer growth, longer sales cycles, and guidance cuts.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#125 $EOSE Battery Boom or Broken Ramp Inside Eos Energy Miss

Dive into the Eos Energy $EOSE controversy as we break down a securities class action tied to battery technology, manufacturing automation, and missed revenue guidance. This episode is for investors, traders, and anyone following energy storage, clean tech, and market risk. Expect deep dives, real case analysis, and insights into production delays, downtime issues, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#124 $DRVN Restatement Shock When Financials Can’t Be Trusted

Dive into the Driven Brands $DRVN controversy as we break down a securities class action tied to financial restatements, internal control failures, and accounting errors across multiple years. This episode is for investors, traders, and anyone following earnings quality, corporate governance, and market risk. Expect deep dives, real case analysis, and insights into unreliable financials, audit issues, and stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#123 $CWH Inventory Control or Margin Collapse Inside Camping World

Dive into the Camping World $CWH controversy as we break down a securities class action tied to inventory management, margin pressure, and alleged misleading statements about financial discipline. This episode is for investors, traders, and anyone following retail stocks, RV market trends, and market risk. Expect deep dives, real case analysis, and insights into inventory missteps, declining margins, and dividend cuts.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#122 $CHOW Pump Hype or Engineered Collapse Inside ChowChow Cloud

Dive into the ChowChow Cloud $CHOW controversy as we break down a securities class action tied to IPO activity, alleged stock manipulation, and social media driven trading schemes. This episode is for investors, traders, and anyone following micro cap stocks, IPO risks, and market volatility. Expect deep dives, real case analysis, and insights into pump and dump patterns, low float risks, and sudden stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#121 $BSX Heart Growth Hype or Hidden Slowdown Inside Boston Scientific

Dive into the Boston Scientific $BSX controversy as we break down a securities class action tied to medical devices, electrophysiology growth, and alleged misleading statements around FARAPULSE adoption. This episode is for investors, traders, and anyone following healthcare stocks, medtech innovation, and market risk. Expect deep dives, real case analysis, and insights into competition, slowing procedure volumes, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed

Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market volatility. Expect deep dives, real case analysis, and insights into regulatory risk, clinical setbacks, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#119 $APO Wall Street Secrets The Apollo Epstein Controversy

Dive into the Apollo Global Management $APO controversy as we break down a securities class action tied to alleged undisclosed ties, reputational risk, and investor disclosures. This episode is for investors, traders, and anyone following hedge funds, Wall Street news, and market transparency. Expect deep dives, real case analysis, and insights into corporate governance, disclosure risks, and stock reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#118 $SNOW Cloud Growth or Hidden Headwinds Inside the Snowflake Drop

Dive into the Snowflake $SNOW controversy as we break down a securities class action tied to cloud computing, consumption based revenue, and unexpected growth headwinds. This episode is for investors, traders, and anyone following tech stocks, data platforms, and market volatility. Expect deep dives, real case analysis, and insights into pricing models, efficiency impacts, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.